

# Reduction in Angiopoietin-Like Protein 3 via RNA Interference Improves Dyslipidemias and Hepatic Steatosis

So C. Wong<sup>1</sup>, Rui Zhu<sup>1</sup>, Peter J. Havel<sup>2</sup>, James Hamilton<sup>1</sup>, James Graham<sup>2</sup>, Julia Hegge<sup>1</sup>, Casi Schienebeck<sup>1</sup>, Gary Christensen<sup>1</sup>, Lucas Trilling<sup>1</sup>, Holly Hamilton<sup>1</sup>, Jeremy Brigg<sup>1</sup>, Meredith Hinkes<sup>1</sup>, Stephanie Bertin<sup>1</sup>, Mark Seefeld<sup>1</sup>, Bruce Given<sup>1</sup> and Zhen Li<sup>1</sup>

<sup>1</sup>Arrowhead Pharmaceuticals Inc., Madison, WI, United States, <sup>2</sup>University of California, Davis, CA, United States




## BACKGROUND

- Hypertriglyceridemia and hyperlipidemia represent causative risks for atherosclerosis, and elevated triglycerides (TG) also manifest as part of the metabolic syndrome and hepatic steatosis
- Human genetic analysis has identified that individuals with loss-of-function mutations in angiopoietin-like protein 3 (ANGPTL3) have very low plasma levels of triglycerides (TGs) and low-density lipoprotein (LDL-C), and a reduced risk of cardiovascular disease
- An RNA interference (RNAi) based therapy using Arrowhead Pharmaceuticals' TRiM™ platform to reduce liver ANGPTL3 production by gene silencing may be an effective approach to treat dyslipidemias and metabolic diseases (AHA 2018)

## TRiM™ Platform

### ARO-ANG3




- Short dsRNA targeting *ANGPTL3* mRNA
- Hepatocyte ASGPr targeting ligand
- Subcutaneous (SQ) dosing
- Designed to reduce production of ANGPTL3 to potentially treat dyslipidemias
- Specific, catalytic and highly efficient

## METHODS

- Highly potent and specific RNAi conjugates cross-reactive to human, rodent and non-human primate-(NHP) *ANGPTL3* transcripts were identified and studied for reductions in serum ANGPTL3 protein and liver *ANGPTL3* mRNA levels
- Lead optimization studies in wild type mice and chow-fed NHPs identified development candidate ARO-ANG3
- Dyslipidemic mouse models and a dyslipidemic fructose-fed NHP model were treated with ARO-ANG3 to examine lipid lowering and metabolic effects

## RESULTS

### Dose response in C57BL/6J wild-type mice, N = 4/group, single SQ injection of ARO-ANG3 (Day 1)




- Dose-dependent reductions in serum ANGPTL3 levels
- Day 29 hepatic *ANGPTL3* mRNA correlated with serum ANGPTL3 reductions

### Reduction of serum lipids in *LDLr* KO mice


Mice on Western diet (n=12) or Standard chow (n=4) ARO-ANG3 injected on Day 1 and 29

- Maximum serum ANGPTL3 reductions of 98-99% (Western diet) and 95-96% (chow)
- TGs reductions of 90% (Western diet) and 48% (chow)
- LDL-C reductions of 48% (Western diet) and 43% (chow) through *LDLr* independent pathways




### Improvements in glucose tolerance and reduction in hepatic steatosis in DIO mice

8 weeks old DIO mice on high fat diet, N=7/group 3 mg/kg ARO-ANG3 on Days 1 and 24 Glucose Tolerance Test on Day 41




- Maximum serum ANGPTL3 reductions of 99% (after second dose)
- Maximum TGs reductions of 54% (from 70 mg/dL to 31 mg/dL)
- Maximum LDL-C reductions of 65% (from 20 mg/dL to 7 mg/dL)



### Single dose duration in chow-fed cynomolgus monkeys


Single 2 mg/kg ARO-ANG3 injected on Day 1, N=3



- Maximum mean serum ANGPTL3 reductions of ~80% sustained for at least 4 weeks after a single 2 mg/kg dose
- Significant reductions in TGs were observed

### Efficacy in a fructose-fed dyslipidemic rhesus monkey model (Bremer et al Clin. Trans. Sci., 2019)

Animals on fructose diet for 6 weeks before dosing 4 mg/kg ARO-ANG3 (N=4), Saline (N=2), SQ injected on Days 1 and 29



- Over 95% maximum reductions in serum ANGPTL3
- 80% maximum mean reductions in TGs
- 20-60% max reductions in LDL-C (not shown)

## CONCLUSIONS

- Our results support an ANGPTL3-targeted RNAi therapeutic as a treatment for dyslipidemia, with potential metabolic benefits
- Results in NHPs suggest human dosing intervals of once every 3 months or longer in ongoing human studies

## ACKNOWLEDGEMENTS

We thank Vladimir Subbotin, Maria Afrazi and Anna Rowe for their contributions in histopathology evaluations; the Arrowhead Laboratory Animal Research team for their excellent animal care and surgical techniques